期刊文献+

非布司他对高尿酸血症患者炎性因子的影响

原文传递
导出
摘要 目的观察不同剂量非布司他对高尿酸血症患者炎性因子的影响。方法选取茂名市人民医院收治的高尿酸血症患者106例,采取数字随机表法分为大剂量组和小剂量组各53例,大剂量组给予非布司他80mg口服治疗,小剂量组给予非布司他40mg口服治疗,对比两组不同剂量非布司他治疗对炎性因子的影响。结果两组患者治疗后IL-6、TNF-α水平均低于治疗前,差异有统计学意义(P<0.05)。大剂量组患者治疗后IL-6、TNF-α水平均低于小剂量组,差异有统计学意义(P<0.05)。大剂量组用药不良反应发生率为3.77%高于小剂量组的1.89%,差异无统计学意义(P>0.05)。结论 80mg的非布司他更有利于患者炎性因子水平的改善,对高尿酸血症患者的治疗有利。
出处 《中国城乡企业卫生》 2017年第5期91-92,共2页 Chinese Journal of Urban and Rural Enterprise Hygiene
  • 相关文献

参考文献5

二级参考文献44

  • 1关宝生,白雪,王艳秋,尹相林,李若男,周宪君,徐辉,杜文彦,邱洪斌.痛风/高尿酸血症患者生活习惯的危险因素[J].中国老年学杂志,2014,34(2):455-457. 被引量:62
  • 2Yokoi K,Adachi H,Hirai Y,et al.Plasma endothelin-1 level is a predictor of 10-year mortality in a general population:the Tanushimaru study[J].Circ J,2012,76(12):2779-2784.
  • 3Cappola TP,Kass DA,Nelson GS,et al.Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy[J].Circulation,2001,104(20):2407-2411.
  • 4Sui X,Church TS,Meriwether RA,et al.Uric acid and the development of metabolic syndrome in women and men[J].Metabolism,2008,57(6):845-852.
  • 5George J,Carr E,Davies J,et al.High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid[J].Circulation,2006,114(23):2508-2516.
  • 6Schumacher HR,Becker MA,Wortmann RL,et al.Effects of febuostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a 28-week,phase Ⅲ,randomized,double-blind,parallel-group trial[J].Arthritis Rheum,2008,59(11):1540-1548.
  • 7Van Beneden R,Gurne O,Selvais PL,et al.Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure:a 7-year follow-up study[J].Card Fail,2004,10(6):490-495.
  • 8Rudijanto A.The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J].Acta Med Indones,2007,39(2):86-93.
  • 9Terkeltauh R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics [J]. Arthritis Res Ther, 2006, 8( Suppl 1) : S4.
  • 10Chao 1, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout [J]. CUff Rheumatol Rep, 2009,11 (2): 135-140.

共引文献172

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部